Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

2.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

3.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

4.

Lesser-known lobular breast cancer on the rise in U.S. women

5.

Prostate cancer death risk is higher in late teens and early 20s weight gain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot